

Atty's Docket:101195-54  
DORKEN et al.,

**AMENDMENT TO THE SPECIFICATION**

Please amend the previously submitted BRIEF DESCRIPTION OF THE DRAWINGS, as follows:

**- Brief Description of the Drawings**

**Fig. 1 - flow chart illustrating the expression cassette;**

**Fig. 2 - flow chart illustrating the simple approach with which therapeutic genes may be removed from, or added to the plasmid, a kind of "box of bricks" system in which the therapeutic genes can be replaced with a low amount of effort;**

**Fig. 3 - chart illustrating the generation of a recombinant adenoviral plasmid plasmide containing the expressing cassette by homologous recombination in the BJ cells;**

**Fig. 4a- graft showing the constitutive promoter leading to a continuous increase of the serum content of hAAT; and**

**Fig. 4b- graft showing the Ad vector with the YB-a promoter leading to a temporarily very high expression with a maximum serum content of hAAT on the third day.**

**On page 6, delete the first paragraph, from pCR2.1 to (see Fig. 2) with the following replacement paragraph.**

pCR2.1 vector of Invitrogen and nucleotide 453-2150 of the YB-1 promoter sequence, gene bank Acc.# X96666). These two elements represent the expression cassette (see Fig. 1). In this, the YB-1 promoter is cloned into an ~~MSE~~ **MCS** of a vector adapted specifically for this purpose in such a way that various therapeutic genes can be put under the control of the promoter without the MCS having to be adapted again. This is a MCS containing a group of specifically selected enzyme restriction sites.

Atty's Docket: 101195-54  
DORKEN et al.,

These restriction sites are to permit a quick and uncomplicated exchange of the therapeutic genes into the expression cassette "downstream" of the promoter. Additional changes to the remaining vector and to the YB-1 promoter already existing are avoided in this way. Thus, there results a simple ~~kind of "box of bricks"~~ system in which the therapeutic genes can be replaced with little ~~a low~~ amount of effort (see Fig. 2).

On page 8, please delete the second and third paragraphs, and replace with the following amended second and third paragraphs, respectively.

The constitutive promoter led to a continuous increase of the serum content of hAAT (Fig. 4A). In contrast ~~contrast~~, the Ad vector with the YB-1 promoter led to a temporarily very high expression with a maximum serum content of hAAT on the third day (Fig. 4B).

1.0x10<sup>9</sup> pfu AdRSV.hAAT (A) or AdYB-1.hAAT (B) was injected intravenously into SCID mice (n=3 for A and B). The serum content of human alpha 1-antitrypsin (hAAT) was determined by means of ELISA. Each bar graph in Fig. 4A and 4B represents the serum hAAT level of a single mouse at the indicated times post infection. Three mice at each time point were tested.